Alexandra Trudeau
Acute Care · Sugar Land, TXNPI 1417420902
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,948 of the $12,182 with a category attached, or 81.7%. It is spread thinly across 31 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 464 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- AbbVie$3K
- Pfizer$811
- UCB, Inc.$714
- Boston Scientific$712
- Abbott$707
- plus $4K from 25 others
What the payments were for
- Travel & lodging$2,18918%
- Food & beverage$9,94882%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 27 | $2,742 |
| AbbVie | 166 | $2,713 |
| Pfizer | 60 | $811 |
| UCB, Inc. | 34 | $714 |
| Boston Scientific | 8 | $712 |
| Abbott | 11 | $707 |
| Acadia Pharmaceuticals Inc | 21 | $560 |
| Neurocrine Biosciences, Inc. | 21 | $553 |
| EMD Serono, Inc. | 17 | $377 |
| AstraZeneca | 12 | $360 |
| Biogen | 14 | $294 |
| Lundbeck LLC | 10 | $227 |
| Novartis | 17 | $214 |
| Eisai Inc. | 8 | $181 |
| Si-bone, Inc. | 1 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| Genentech USA, Inc. | 5 | $112 |
| Lilly USA, LLC | 5 | $102 |
| SK Life Science, Inc. | 1 | $99 |
| Amneal Pharmaceuticals LLC | 5 | $86 |
| Azurity Pharmaceuticals, Inc. | 3 | $55 |
| Merz Pharmaceuticals, LLC | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $49 |
| Harmony Biosciences LLC | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $32 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $31 |
| Cala Health, Inc. | 1 | $23 |
| Livanova USA, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| Aucta Pharmaceuticals, Inc. | 1 | $16 |
| Augmedics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA PC$1,636
- VERCISE$439
- INFINITY$431
- PERCEPT PC BRAINSENSE$374
- iFuse Implant$149
- QULIPTA$125
- UBRELVY$125
- BRILINTA$122
How this compares
$12,182 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 21 | $174,515 |
| UbrelvyUbrogepant | 15 | $22,241 |
| RytaryCarbidopa/Levodopa | 11 | $11,724 |
| NeuproRotigotine | 11 | $9,147 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 96 | $5,270 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 180 | $3,723 |
| Memantine Hcl | 28 | $1,535 |
| Pregabalin | 18 | $924 |
| Gabapentin | 38 | $916 |
| Propranolol Hcl ErPropranolol Hcl | 22 | $834 |
| Propranolol Hcl | 29 | $495 |
| Duloxetine Hcl | 38 | $486 |
| Primidone | 13 | $480 |
| Donepezil Hcl | 53 | $440 |
| Topiramate | 30 | $439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $553 | $174,51521 claims |
| AbbVieUbrelvy | $2,713 | $22,24115 claims |
| Amneal Pharmaceuticals LLCRytary | $86 | $11,72411 claims |
| UCB, Inc.Neupro | $714 | $9,14711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in Sugar Land
- Bahia ElkamandSugar Land$23K
- Summer WaughSugar Land$15K
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
- Afton DickersonHouston$27K
- Eleanor WeltgeHouston$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.